Sign In
Buy PODD
$143.30
+0.87 (+0.611%)
At Close: Jun 03, 2026
3 Tariff-Proof Medical Device Stocks to Watch Amid Trump's MAGA Slogan
12:06pm, Wednesday, 19'th Mar 2025
Tariffs are shaking up the Medical Device industry, but SYK, MDT & PODD are poised to thrive. Here's why three key players remain strong despite rising trade tensions.
Insulet Announces Pricing of Senior Notes Due 2033
04:32pm, Tuesday, 18'th Mar 2025
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, has
Insulet Announces Proposed Financing Transactions
07:35am, Tuesday, 18'th Mar 2025
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, toda
Insulet Leans Bullish (Technical Analysis)
11:53pm, Monday, 17'th Mar 2025
PODD exhibits bullish price action with a series of higher highs and lows, trading above its upward sloping 30-week EMA since August 2024. Momentum is long-term bullish but short-term bearish, with th
Insulet to Host Investor Day on June 5, 2025
06:00am, Tuesday, 11'th Mar 2025
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host an Inv
Insulet Sales Keep Rising
08:04am, Wednesday, 26'th Feb 2025
Insulet Corporation (PODD) continues its strong sales and growth trend.
Insulet's Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst
01:28pm, Friday, 21'st Feb 2025
On Thursday, Insulet Corporation PODD reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the consensus of $1.02.
PODD Stock Falls Despite Q4 Earnings and Revenue Beat, Margins Rise
09:40am, Friday, 21'st Feb 2025
Insulet's fourth-quarter results benefit from the continued high demand for Omnipod 5.
Insulet Corporation (PODD) Q4 2024 Earnings Call Transcript
11:37pm, Thursday, 20'th Feb 2025
Insulet Corporation (NASDAQ:PODD ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants June Lazaroff - Senior Director of Investor Relations Jim Hollingshead - President
Compared to Estimates, Insulet (PODD) Q4 Earnings: A Look at Key Metrics
06:30pm, Thursday, 20'th Feb 2025
While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compar
Insulet (PODD) Q4 Earnings and Revenues Top Estimates
06:15pm, Thursday, 20'th Feb 2025
Insulet (PODD) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $1.40 per share a year ago.
Insulet beats quarterly profit estimates on insulin pump demand
04:55pm, Thursday, 20'th Feb 2025
Insulet reported a higher-than-expected profit in the fourth quarter on Thursday, driven by strong demand for its wearable insulin pumps.
Insulet Reports Full Year 2024 Revenue Increase of 22% and Fourth Quarter 2024 Revenue Increase of 17% Year-Over-Year
04:01pm, Thursday, 20'th Feb 2025
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced
Stay Ahead of the Game With Insulet (PODD) Q4 Earnings: Wall Street's Insights on Key Metrics
10:21am, Friday, 14'th Feb 2025
Beyond analysts' top -and-bottom-line estimates for Insulet (PODD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter
NVIDIA & 2 Other Profitable Stocks to Buy in February
04:05pm, Friday, 31'st Jan 2025
NVIDIA, AppLovin and Insulet have been selected as the top picks with a high net income ratio.
